Amphastar Pharmaceuticals Net Profit Margin 2012-2026 | AMPH
Amphastar Pharmaceuticals net profit margin from 2012 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Amphastar Pharmaceuticals Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2026-03-31 | $0.72B | $0.08B | 10.83% |
| 2025-12-31 | $0.72B | $0.10B | 13.47% |
| 2025-09-30 | $0.72B | $0.11B | 15.33% |
| 2025-06-30 | $0.72B | $0.13B | 18.53% |
| 2025-03-31 | $0.73B | $0.14B | 19.29% |
| 2024-12-31 | $0.73B | $0.16B | 21.72% |
| 2024-09-30 | $0.72B | $0.16B | 21.72% |
| 2024-06-30 | $0.71B | $0.17B | 23.28% |
| 2024-03-31 | $0.68B | $0.15B | 22.75% |
| 2023-12-31 | $0.65B | $0.14B | 21.24% |
| 2023-09-30 | $0.60B | $0.14B | 22.43% |
| 2023-06-30 | $0.54B | $0.10B | 18.85% |
| 2023-03-31 | $0.52B | $0.09B | 17.95% |
| 2022-12-31 | $0.50B | $0.09B | 18.27% |
| 2022-09-30 | $0.48B | $0.08B | 15.91% |
| 2022-06-30 | $0.48B | $0.09B | 19.12% |
| 2022-03-31 | $0.46B | $0.08B | 18.02% |
| 2021-12-31 | $0.44B | $0.06B | 14.38% |
| 2021-09-30 | $0.41B | $0.04B | 8.96% |
| 2021-06-30 | $0.38B | $0.01B | 2.86% |
| 2021-03-31 | $0.37B | $0.00B | 0.82% |
| 2020-12-31 | $0.35B | $0.00B | 0.57% |
| 2020-09-30 | $0.34B | $0.01B | 2.08% |
| 2020-06-30 | $0.33B | $0.00B | 1.20% |
| 2020-03-31 | $0.33B | $0.05B | 15.90% |
| 2019-12-31 | $0.32B | $0.05B | 15.22% |
| 2019-09-30 | $0.33B | $0.05B | 15.81% |
| 2019-06-30 | $0.33B | $0.05B | 16.31% |
| 2019-03-31 | $0.32B | $0.00B | 0.63% |
| 2018-12-31 | $0.30B | $-0.01B | -2.03% |
| 2018-09-30 | $0.27B | $-0.01B | -2.64% |
| 2018-06-30 | $0.25B | $-0.01B | -3.64% |
| 2018-03-31 | $0.24B | $0.00B | -1.66% |
| 2017-12-31 | $0.24B | $0.00B | 1.67% |
| 2017-09-30 | $0.24B | 0 | 0.00% |
| 2017-06-30 | $0.25B | $0.00B | 1.60% |
| 2017-03-31 | $0.25B | $0.01B | 3.56% |
| 2016-12-31 | $0.26B | $0.01B | 3.92% |
| 2016-09-30 | $0.27B | $0.02B | 7.84% |
| 2016-06-30 | $0.27B | $0.01B | 5.22% |
| 2016-03-31 | $0.25B | 0 | 0.00% |
| 2015-12-31 | $0.25B | $0.00B | -1.19% |
| 2015-09-30 | $0.23B | $-0.01B | -6.06% |
| 2015-06-30 | $0.23B | $-0.02B | -7.05% |
| 2015-03-31 | $0.22B | $-0.01B | -4.50% |
| 2014-12-31 | $0.21B | $-0.01B | -5.21% |
| 2014-09-30 | $0.21B | $-0.01B | -2.86% |
| 2014-06-30 | $0.21B | $0.00B | -0.48% |
| 2014-03-31 | $0.22B | $0.01B | 3.59% |
| 2013-12-31 | $0.23B | $0.01B | 5.22% |
| 2013-09-30 | $0.23B | $0.01B | 6.17% |
| 2013-06-30 | $0.23B | $0.02B | 7.56% |
| 2013-03-31 | $0.21B | $0.01B | 6.64% |
| 2012-12-31 | $0.20B | $0.02B | 8.82% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |